Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer Journal Article
| Authors: | Markman, M.; Hakes, T.; Barakat, R.; Curtin, J.; Almadrones, L.; Hoskins, W. |
| Article Title: | Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer |
| Abstract: | Purpose: To examine the short-term and long-term results of paclitaxel therapy in patients with advanced heavily pretreated, cisplatin-refractory ovarian cancer. Patients and Methods: The results of treatment for patients entered onto National Cancer Institute (NCI) Treatment Referral Center protocol 9103 at the Memorial Sloan-Kettering Cancer Center (MSKCC) were reviewed to evaluate toxicity, efficacy, and survival. Results: Of 46 individuals with measurable disease treated on the protocol at MSKCC, the objective response rate was only 4%. However, the 2- and 3-year survival rates for all 103 patients (including both measurable and nonmeasurable populations) entered onto this study at MSKCC were 18% and 11%, respectively. Twenty-one percent of patients received ≥ six courses of paclitaxel, which suggests treatment-related stabilization of disease may have had a greater impact on the natural history of the malignancy than indicated by the objective response rate. Conclusion: This experience supports the hypothesis that a more prolonged delivery of paclitaxel (ie, > six courses), a cell- cycle-specific cytotoxic agent with limited or no cumulative toxicity, may result in an improved therapeutic outcome in ovarian cancer. This concept will need to be tested in a randomized phase 3 clinical trial. |
| Keywords: | adult; cancer chemotherapy; cancer survival; human tissue; treatment outcome; aged; middle aged; survival analysis; survival rate; human cell; major clinical study; clinical trial; neutropenia; cisplatin; drug efficacy; paclitaxel; follow-up studies; ovarian neoplasms; ovary cancer; peritoneal neoplasms; thrombocytopenia; carcinoma, papillary; antineoplastic agents, phytogenic; ca 125 antigen; recombinant granulocyte colony stimulating factor; intravenous drug administration; subcutaneous drug administration; humans; human; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 14 |
| Issue: | 3 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1996-03-01 |
| Start Page: | 796 |
| End Page: | 799 |
| Language: | English |
| PUBMED: | 8622026 |
| PROVIDER: | scopus |
| DOI: | 10.1200/JCO.1996.14.3.796 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 22 November 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work